Skip to content

Impel Neuropharma

Description

Impel NeuroPharma’s Pressurized Olfactory Delivery (POD) device delivers aerosolized drugs to the upper nasal cavity where they are directly transported into the brain, effectively bypassing the blood-brain barrier. The POD device enables molecules to become therapeutics that were previously unable to cross the blood-brain barrier, and often allows less drug volume to be utilized, lowering plasma exposure and reducing systemic side effects.

Team Members

Michael Hite

Co-founder and CEO

John Hoekman

Co-founder and Chief Scientific Officer

H. Stewart Parker

Member of the Board of Directors